Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer

• Status: Recruiting
• Trial end date: 2023-04-19
• Target enrollment: 0
• Participant gender: All

Summary

Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hui Bu
• Treatments: Nimotuzumab

Criteria

Inclusion Criteria:

• age 18 years or older, gender not limited;

• A definite diagnosis of Leptomeningeal metastases from lung cancer, including cerebrospinal fluid cytology and/or neuroimaging;

• Have a clear history of lung cancer, including histopathological diagnosis, or cytopathology combined with imaging diagnosis

• Patients who received any of EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib etc.) meet the diagnostic criteria for secondary resistance and were in a slow progression stage

• Detection results of cerebrospinal fluid, blood gene or lung tissue specimens showed EGFR mutation, and immunohistochemistry results of cerebrospinal fluid, blood gene or lung tissue showed positive EGFR expression

• Bone marrow, liver, kidneys and blood clotting function are relatively stable

Exclusion Criteria:

• Eastern Cooperative Oncology Group scored > 2 points

• Patients had poor compliance, or for other reasons the investigator considered them unsuitable to participate in the study